Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04529824 · ClinicalTrials.gov registry record
Glucose Risk Assessment in Employer Populations
A clinical trial of Diabetes and PreDiabetes, sponsored by DexCom.
- Completed
- Registry status
- 207
- Enrollment target
- 1
- Study location
NCT04529824: Completed study of Diabetes and PreDiabetes, sponsored by DexCom.
NCT04529824 is a study of Diabetes and PreDiabetes that has completed, run by DexCom. The registered enrollment target is 207 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04529824, a study of Diabetes and PreDiabetes, has completed, sponsored by DexCom.
- COMPLETED
- Registry status
- 207 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an observational study to understand the glucose characteristics of the general population (normal glucose, pre-diabetes, and diabetes). Glucose risk will be measured with laboratory HbA1c and continuous glucose monitor (CGM) derived metrics. Physical activity will also be measured using a Fitbit activity tracker. The study will inform future programs that use CGM and activity tracking to identify people at risk for diabetes in the population.
Primary Outcome
diabetes status will be determined by A1C record or clinically measured point-of-care A1C (no diabetes \<5.7%, pre-diabetes 5.7% to 6.4%, and diabetes \> or = to 6.5%).
Conditions Studied
Interventions
- DEVICE Dexcom G6 Continuous Glucose Monitor (CGM) System
Study Locations (1)
Florida
- Lakeland Clinic - Lakeland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-08-01 |
What the finished NCT04529824 record still lists
NCT04529824 is an observational study that tracks outcomes without assigning an intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Dexcom G6 Continuous Glucose Monitor (CGM) System is the first listed.
NCT04529824 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04529824 about?
NCT04529824 is a clinical study titled "Glucose Risk Assessment in Employer Populations". This is an observational study to understand the glucose characteristics of the general population (normal glucose, pre-diabetes, and diabetes). Glucose risk will be measured with laboratory HbA1c and continuous glucose monitor (CGM) derived metrics. Physical activity will also be measured using a F...
What is the current status of trial NCT04529824?
This trial is currently completed. The enrollment target is 207 participants. The study started on 2019-04-01. Estimated completion is 2021-08-01.
What conditions does trial NCT04529824 study?
This clinical trial studies the following conditions: Diabetes, PreDiabetes, Glucose Intolerance.
What interventions are being tested in trial NCT04529824?
The interventions under investigation include: Dexcom G6 Continuous Glucose Monitor (CGM) System (DEVICE).
Who is sponsoring clinical trial NCT04529824?
This trial is sponsored by DexCom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04529824 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04529824's enrollment target sits among peer trials
207 145th of 338 higher than 194 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DFC 004 Biomarkers for Active Diabetic Foot Ulcers
RECRUITING
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Taste Bud-Derived Stem Cells in Humans
RECRUITING
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI